Home




Clinical Trial Results

关于阿帕替尼治疗难治性转移性结直肠癌的单组 II 期研究
A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
Xiaofeng Chen, Tianzhu Qiu, Yingwei Zhu, Jing Sun, Ping Li, Biao Wang, Peinan Lin, Xiaomin Cai, Xiao Han, Fengjiao Zhao, Yongqian Shu, Lianpeng Chang, Hua Jiang, Yanhong Gu
The Oncologist 2019; 24:883-e407; first published on March 15, 2019; doi:10.1634/theoncologist.2019-0164

0.1% 阿达帕林凝胶与安慰剂对抗表皮生长因子受体诱发的痤疮样皮疹的预防作用:左右随机对比评估(APPEARANCE研究)
Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)
Naoko Chayahara, Toru Mukohara, Motoko Tachihara, Yoshimi Fujishima, Atsushi Fukunaga, Ken Washio, Masatsugu Yamamoto, Kyosuke Nakata, Kazuyuki Kobayashi, Kei Takenaka, Masanori Toyoda, Naomi Kiyota, Kazutoshi Tobimatsu, Hisayo Doi, Naomi Mizuta, Naho Marugami, Atsushi Kawaguchi, Chikako Nishigori, Yoshihiro Nishimura, Hironobu Minami
The Oncologist 2019; 24:885-e413; first published on March 19, 2019; doi:10.1634/theoncologist.2019-0156

Selinexor (KPT-330) 治疗转移性三阴性乳腺癌的 II 期试验
A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
Michael Shafique, Roohi Ismail‐Khan, Martine Extermann, Dan Sullivan, Dawn Goodridge, David Boulware, Deanna Hogue, Hatem Soliman, Hung Khong, Hyo S. Han
The Oncologist 2019; 24:887-e416; first published on April 17, 2019; doi:10.1634/theoncologist.2019-0231

唑来膦酸辅助治疗高危骨巨细胞瘤:多中心随机 II 期试验研究
Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
Astrid Lipplaa, Judith R. Kroep, Lizz van der Heijden, Paul C. Jutte, Pancras C.W. Hogendoorn, Sander Dijkstra, Hans Gelderblom
The Oncologist 2019; 24:889-e421; first published on April 30, 2019; doi:10.1634/theoncologist.2019-0280

纳武单抗在经治的晚期或复发性鼻咽癌和其他实体肿瘤中的 I/II 期开放标签研究
A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
Yuxiang Ma, Wenfeng Fang, Yang Zhang, Yunpeng Yang, Shaodong Hong, Yuanyuan Zhao, Amol Tendolkar, Lu Chen, Dong Xu, Jennifer Sheng, Hongyun Zhao, Li Zhang
The Oncologist 2019; 24:891-e431; first published on May 2, 2019; doi:10.1634/theoncologist.2019-0284


Breast Cancer

依维莫司加依西美坦治疗激素受体阳性晚期乳腺癌:BOLERO-2 的 PAM50 内在亚型分析
Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2
Aleix Prat, Jan Christoph Brase, Yuan Cheng, Paolo Nuciforo, Laia Paré, Tomás Pascual, Débora Martínez, Patricia Galván, Maria Vidal, Barbara Adamo, Gabriel N. Hortobagyi, José Baselga, Eva Ciruelos
The Oncologist 2019; 24:893-900; first published on January 24, 2019; doi:10.1634/theoncologist.2018-0407

乳腺混合浸润性导管和小叶癌:预后和组织学分级的重要性
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade
Otto Metzger‐Filho, Arlindo R. Ferreira, Rinath Jeselsohn, William T. Barry, Deborah A. Dillon, Jane E. Brock, Ines Vaz‐Luis, Melissa E. Hughes, Eric P. Winer, Nancy U. Lin
The Oncologist 2019; 24:e441-e449; first published on December 5, 2018; doi:10.1634/theoncologist.2018-0363


Gastrointestinal Cancer

高级别胃肠道神经内分泌肿瘤治疗和预后:国家癌症数据库研究
High‐Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study
Olatunji B. Alese, Renjian Jiang, Walid Shaib, Christina Wu, Mehmet Akce, Madhusmita Behera, Bassel F. El‐Rayes
The Oncologist 2019; 24:911-920; first published on November 27, 2018; doi:10.1634/theoncologist.2018-0382

关于序贯或同步 FOLFOXIRI-贝伐单抗对比 FOLFOX-贝伐单抗治疗转移性结直肠癌的 II 期随机试验 (STEAM)
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Herbert I. Hurwitz, Benjamin R. Tan, James A. Reeves, Henry Xiong, Brad Somer, Heinz‐Josef Lenz, Howard S. Hochster, Frank Scappaticci, John F. Palma, Richard Price, John J. Lee, Alan Nicholas, Nicolas Sommer, Johanna Bendell
The Oncologist 2019; 24:921-932; first published on December 14, 2018; doi:10.1634/theoncologist.2018-0344

在真实世界临床环境中将瑞戈非尼用于治疗日本转移性结直肠癌患者的大规模、前瞻性观察研究
Large‐Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real‐World Clinical Setting
Kensei Yamaguchi, Yoshito Komatsu, Taroh Satoh, Hiroyuki Uetake, Takayuki Yoshino, Toshirou Nishida, Naoya Yamazaki, Hajime Takikawa, Takashi Morimoto, Masayuki Chosa, Toshiyuki Sunaya, Yoko Hamada, Kei Muro, Kenichi Sugihara
The Oncologist 2019; 24:e450-e457; first published on January 3, 2019; doi:10.1634/theoncologist.2018-0377


Global Health and Cancer

中国肿瘤学家的职业倦怠和职业满意度:一项全国调查
Prevalence of Burnout and Career Satisfaction Among Oncologists in China: A National Survey
Shuxiang Ma, Yan Huang, Yunpeng Yang, Yuxiang Ma, Ting Zhou, Hongyun Zhao, Likun Chen, Ningning Zhou, Li Zhang
The Oncologist 2019; 24:e480-e489; first published on December 19, 2018; doi:10.1634/theoncologist.2018-0249

Côte d’Or 的长期妇科癌症幸存者:健康相关的生活质量和生活条件
Long‐Term Gynecological Cancer Survivors in Côte d'Or: Health‐Related Quality of Life and Living Conditions
Ariane Mamguem Kamga, Agnès Dumas, Florence Joly, Oumar Billa, Julien Simon, Marie‐Laure Poillot, Ariane Darut‐Jouve, Charles Coutant, Pierre Fumoleau, Patrick Arveux, Tienhan Sandrine Dabakuyo‐Yonli
The Oncologist 2019; 24:e490-e500; first published on December 21, 2018; doi:10.1634/theoncologist.2018-0347


Health Outcomes and Economics of Cancer Care

脑转移和相关神经认知评分对 EGFR 突变和 ALK 重排 NSCLC 健康效用评分的影响:真实世界循证分析
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis
Grainne M. O'Kane, Jie Su, Brandon C. Tse, Vivian Tam, Tiffany Tse, Lin Lu, Michael Borean, Emily Tam, Catherine Labbé, Hiten Naik, Nicole Mittmann, Mark K. Doherty, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, Nadine M. Richard, Kim Edelstein, David Shultz, M. Catherine Brown, Wei Xu, Doris Howell, Geoffrey Liu
The Oncologist 2019; 24:e501-e509; first published on April 5, 2019; doi:10.1634/theoncologist.2018-0544


Hepatobiliary

伴发热肝内胆管癌患者的临床特征及预后因素:倾向评分匹配分析
Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis
Zi‐Jun Gong, Jian‐Wen Cheng, Pin‐Ting Gao, Ao Huang, Yun‐Fan Sun, Kai‐Qian Zhou, Bo Hu, Shuang‐Jian Qiu, Jian Zhou, Jia Fan, Xin‐Rong Yang
The Oncologist 2019; 24:997-1007; first published on March 25, 2019; doi:10.1634/theoncologist.2018-0268


Lung Cancer

达拉非尼和曲美替尼联合治疗 BRAF V600E 突变型非小细胞肺癌患者的不良反应管理
Adverse Event Management in Patients with BRAF V600E‐Mutant Non‐Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
Anna Chalmers, Laura Cannon, Wallace Akerley
The Oncologist 2019; 24:963-972; first published on December 31, 2018; doi:10.1634/theoncologist.2018-0296

在恶性胸膜间皮瘤经过术前放疗和胸膜外肺切除术出现复发之后,系统治疗的使用和结果
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
Sara V. Soldera, John Kavanagh, Melania Pintilie, Natasha B. Leighl, Marc de Perrot, John Cho, Andrew Hope, Ronald Feld, Penelope A. Bradbury
The Oncologist 2019; 24:e510-e517; first published on November 26, 2018; doi:10.1634/theoncologist.2018-0501


Sarcomas

在标准的多模式治疗失败后,将阿帕替尼用于治疗晚期骨肉瘤:开放标签 II 期临床试验
Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
Lu Xie, Jie Xu, Xin Sun, Xiaodong Tang, Taiqiang Yan, Rongli Yang, Wei Guo
The Oncologist 2019; 24:e542-e550; first published on December 17, 2018; doi:10.1634/theoncologist.2018-0542


Brief Communications

支气管冲洗液诊断早期肺癌的可行性研究
Feasibility of Bronchial Washing Fluid‐Based Approach to Early‐Stage Lung Cancer Diagnosis
Jeong‐Seon Ryu, Jun Hyeok Lim, Myoung Kyu Lee, Seung Jae Lee, Hyun‐Jung Kim, Min Jeong Kim, Mi Hwa Park, Jung Soo Kim, Hae‐Seong Nam, Nuri Park, Seok Joong Yong
The Oncologist 2019; 24:e603-e606; first published on April 29, 2019; doi:10.1634/theoncologist.2019-0147